The alpha, twice a week
That was 5 min.
Get the best new moments in your inbox every Wednesday and Saturday. It's free.
Check your inbox
We sent a link to your address. Click it to finish signing up. Not there in a minute? Look in spam.
or
How I Invest · 5 min · Nov 16, 2026
Seed valuations have weakened Baylor’s case for early-stage venture
Renee Hanna says seed prices near $700 million make venture outcomes harder to underwrite, so Baylor favors specialized GPs and later, more derisked rounds.
In this episode
Full analysis- 5:50Expansion capital can compound more reliably than early venture3 min
- 13:24A concentrated portfolio helps Baylor focus capital and timePro pick 6 min
- 49:31Later-stage venture can offer attractive risk-adjusted returns3 min
- 1:22Seed valuations have weakened Baylor’s case for early-stage venture5 min
- 11:07Baylor seeks upside without depending on power-law returns3 min
- 26:58Baylor requires a 15% net IRR to justify illiquidity3 min
- 36:11Baylor sees room for data-rich software firms to adopt AI3 min
- 43:41Active managers should move capital toward stronger opportunities5 min
“For us, the biggest hurdle is just the entry valuations have changed so much at the pre seed and seed stage rounds.”
Takeaways
- Seed prices near $700 million raise the required market-size bar.
- Specialized GPs can have a clearer right to win in narrow sectors.
- Baylor avoids locking co-investment capital into one name for 12–15 years.
About this segment
Renee Hanna says seed prices near $700 million make venture outcomes harder to underwrite, so Baylor favors specialized GPs and later, more derisked rounds. Its direct investments also need a clearer path to liquidity.
Renee Hanna is a Managing Director of Investments at Baylor University.
Oversees Baylor’s private investments across categories and geographies, bringing nearly two decades of endowment experience.

David Weisburd, Host
From “Baylor Endowment on Rethinking Venture Capital, Concentrated Portfolios, and Power of Compounding”, Nov 16, 2026. Watch the full episode
Thanks. We'll look at and fix what's off.
Transcript
From the transcript How I Invest publishes with the episode.
- 1:34
And last time we chatted, you said something really interesting, which is you used to operate under this framework that venture managers should get into companies as early as possible. Today, you're not so sure. Why not? For us, the biggest hurdle is just the entry valuations have changed so much at the pre seed and seed stage rounds. And so when you look at the entry price, and we still think it absolutely matters what you pay for these assets, when you're paying an average price of closer to $700,000,000 And that's the seed round.
- 2:03
The seed round. We're skeptical about, how large the TAM needs to be for us to get the outcomes that we need to make the venture math work, given the duration of the holding period. So in other words, it might make sense to wait a little bit and maybe get in at $1,500,000,000, but it's massively more derisked than three x. Yeah. Absolutely. And we were talking about before we started recording, like, does a pre seed and seed manager even play an environment like today, given their fund size and their portfolio constructions?
- 2:33
What do you see the top GPs doing today? There's a variety of ways to play it. I can tell you the GPs that we're attracted to are the ones that have a specialization, a certain right to win. And so, we've leaned into groups that have a FinTech specialization. We have a manager that's focused on digital health, and that's all they do, but they're an ex operator. And we feel like they really have a right to win in that space.
- 2:54
We've refined the strike zone for the GP that we think would give them more access. It sounds like the specialization is more important for you for getting into the top deals versus knowing which deals to go into. Is that just a matter of the environment today? For us, knowing which deals to get into at a very, very early stage is really hard, right, which is why we're happy to go into later stage rounds when you have product market fit.
- 3:18
We're leveraging intel from existing GP. There could be a path to IPO over the next three to five years, and you're definitely capping your return, but feel more comfortable about the certainty of that return versus, quite a bit of zeros when you're going early stage. But this is your direct investing platform. So we last chatted, I think, three sixty episodes ago. How has that evolved over the last couple of years, given that current environment?
- 3:42
We've had the benefit of really great access with our existing GP network, where they've got some pro rata rights that they've shared with Baylor, we're able to double down on those opportunities. We've also changed our view a bit on later stage investing, whereas before, it was just something that we shied away from, and clearly we've missed some of those opportunities. But today we're more willing to leverage the network that we have.
- 4:09
We have some great GPs in our portfolio, so we feel very comfortable with their selection process and the returns that we'll be able to recoup, with these guys and able to layer in that exposure that we just weren't doing a ton of before. Talk to me about your process and when you decide to directly invest into a startup. I'll back it up to how we think about investing and where venture sits in our portfolio, because candidly it's a bit more muted relative to what we do across the portfolio.
- 4:33
Early stage venture for us is roughly 10% of the overall portfolio. Another 10% is going to be in later stage opportunities. And the balance is going to be in expansion capital and buyouts across the lower middle market. So, to date, when we've leaned into a co investment opportunity, a more direct investment, It's been through the lens of leveraging our pre existing GP network and feeling very comfortable with their research, the path, and the line of sight to liquidity for us from here.
- 5:05
I think liquidity is one of the big things that we focus on when we're going into co investment. You won't see Baylor lock up capital for a twelve to fifteen year run-in a co investment opportunity. It's just too long of a life for us in a single name. We understand the duration risk you're taking when you go into early stage venture in a fund. We're just not willing to do it on one isolated name.
- 5:25
It's just... It's not what we're good at. And how do you underwrite the duration on direct investments? Typically, it's gonna be something that has more of a path of a three to five x in three to five years. And in terms of liquidity, you're just looking for something with a certain amount of revenue? For liquidity, we want, a clear path to liquidity and a line of sight to either an IPO or an M and A outcome.
- 5:48
I wanna take a step back.